IL263165A - Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment - Google Patents

Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment

Info

Publication number
IL263165A
IL263165A IL263165A IL26316518A IL263165A IL 263165 A IL263165 A IL 263165A IL 263165 A IL263165 A IL 263165A IL 26316518 A IL26316518 A IL 26316518A IL 263165 A IL263165 A IL 263165A
Authority
IL
Israel
Prior art keywords
antibody against
lymphoma
treatment
combination
antibody
Prior art date
Application number
IL263165A
Other languages
English (en)
Hebrew (he)
Inventor
Benedetto Farsaci
Neil Josephson
Anthony Cao
Ryan Heiser
Original Assignee
Seattle Genetics Inc
Bristol Myers Squibb Co
Benedetto Farsaci
Neil Josephson
Anthony Cao
Ryan Heiser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL263165(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc, Bristol Myers Squibb Co, Benedetto Farsaci, Neil Josephson, Anthony Cao, Ryan Heiser filed Critical Seattle Genetics Inc
Publication of IL263165A publication Critical patent/IL263165A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL263165A 2016-06-02 2018-11-21 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment IL263165A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344866P 2016-06-02 2016-06-02
US201662382839P 2016-09-02 2016-09-02
PCT/US2017/035521 WO2017210473A1 (en) 2016-06-02 2017-06-01 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment

Publications (1)

Publication Number Publication Date
IL263165A true IL263165A (en) 2018-12-31

Family

ID=59067913

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263165A IL263165A (en) 2016-06-02 2018-11-21 Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment

Country Status (20)

Country Link
US (2) US11299543B2 (cg-RX-API-DMAC7.html)
EP (2) EP3464368B1 (cg-RX-API-DMAC7.html)
JP (3) JP7641704B2 (cg-RX-API-DMAC7.html)
KR (3) KR102710067B1 (cg-RX-API-DMAC7.html)
CN (1) CN109476752A (cg-RX-API-DMAC7.html)
AU (2) AU2017274444B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018074619A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026246A1 (cg-RX-API-DMAC7.html)
DK (1) DK3464368T3 (cg-RX-API-DMAC7.html)
ES (1) ES2951650T3 (cg-RX-API-DMAC7.html)
FI (1) FI3464368T3 (cg-RX-API-DMAC7.html)
HU (1) HUE063911T2 (cg-RX-API-DMAC7.html)
IL (1) IL263165A (cg-RX-API-DMAC7.html)
MX (2) MX390955B (cg-RX-API-DMAC7.html)
NZ (1) NZ748650A (cg-RX-API-DMAC7.html)
PL (1) PL3464368T3 (cg-RX-API-DMAC7.html)
PT (1) PT3464368T (cg-RX-API-DMAC7.html)
SG (2) SG10202101062YA (cg-RX-API-DMAC7.html)
SI (1) SI3464368T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017210473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
MX390955B (es) 2016-06-02 2025-03-19 Seagen Inc Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
WO2019075188A1 (en) * 2017-10-13 2019-04-18 Seattle Genetics, Inc. MODULATION OF IMMUNE RESPONSE USING CONJUGATES ANTIBODY-MEDICINE
EP3737696A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
SG11202010993VA (en) * 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EP3902838A4 (en) 2018-12-26 2022-12-21 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
AU2020351751A1 (en) 2019-09-25 2022-04-21 Seagen Inc. Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
CA3164124A1 (en) 2019-12-09 2021-06-17 Seagen Inc. Combination therapy with liv1-adc and pd-1 antagonist
CN111407894B (zh) * 2020-02-21 2022-04-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物
IL298155A (en) * 2020-05-13 2023-01-01 Seagen Inc Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
CA3211463A1 (en) 2021-03-01 2022-09-09 Nantbio, Inc. Anti-cd30 monoclonal antibodies and chimeric antigen receptors
CN118987233A (zh) * 2024-08-08 2024-11-22 武汉科技大学 治疗经典型霍奇金淋巴瘤的药物组合物及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1210428E (pt) * 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
CL2007003622A1 (es) * 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014124227A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
EP3521312B1 (en) * 2013-02-20 2021-04-07 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015088847A1 (en) * 2013-12-11 2015-06-18 Glaxosmithkline Llc Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
PL3463457T3 (pl) 2016-06-02 2023-08-21 Bristol-Myers Squibb Company Blokada pd-1 niwolumabem w opornym chłoniaku hodgkina
MX390955B (es) 2016-06-02 2025-03-19 Seagen Inc Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.

Also Published As

Publication number Publication date
JP2024020202A (ja) 2024-02-14
EP4248989A2 (en) 2023-09-27
EP3464368B1 (en) 2023-06-28
PT3464368T (pt) 2023-08-17
JP2019517505A (ja) 2019-06-24
KR20240145059A (ko) 2024-10-04
US11299543B2 (en) 2022-04-12
MX2022003571A (es) 2022-04-25
BR112018074619A2 (pt) 2019-03-06
KR102710067B1 (ko) 2024-09-26
NZ748650A (en) 2025-11-28
AU2017274444B2 (en) 2024-08-01
SG10202101062YA (en) 2021-03-30
MX390955B (es) 2025-03-19
EP4248989A3 (en) 2023-12-27
DK3464368T3 (da) 2023-10-02
AU2024227762A1 (en) 2024-11-21
ES2951650T3 (es) 2023-10-24
EP3464368A1 (en) 2019-04-10
JP2022176973A (ja) 2022-11-30
US20190218293A1 (en) 2019-07-18
MX2018014610A (es) 2019-02-28
SI3464368T1 (sl) 2023-10-30
US20220298243A1 (en) 2022-09-22
WO2017210473A1 (en) 2017-12-07
KR20190008962A (ko) 2019-01-25
HUE063911T2 (hu) 2024-02-28
FI3464368T3 (fi) 2023-09-12
AU2017274444A1 (en) 2018-12-13
CA3026246A1 (en) 2017-12-07
SG11201810454YA (en) 2018-12-28
PL3464368T3 (pl) 2023-08-28
CN109476752A (zh) 2019-03-15
KR20230119265A (ko) 2023-08-16
JP7641704B2 (ja) 2025-03-07

Similar Documents

Publication Publication Date Title
IL263165A (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL257105A (en) Modified cells and methods of therapy
DK3500299T3 (da) Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
HRP20190516T1 (hr) Molekula protutijela protiv pd-1 i njihove uporabe
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
DK2853289T3 (da) Anordning, der kan implanteres under huden
EP3756605C0 (en) SKIN TREATMENT DEVICE
SI3518783T1 (sl) Naprava za zmanjševanje tkiva
HUE066603T2 (hu) ARGX-110 anti-CD70 antitest alkalmazása akut mieloid leukémia kezelésére
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
SI3134124T1 (sl) Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka
EP3197552C0 (en) SKIN TREATMENT DEVICE WITH INTERCHANGEABLE PART
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3419681T3 (da) Medicinsk indretning med hydrofil belægning